<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs that affect bone metabolism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs that affect bone metabolism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drugs that affect bone metabolism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold N Rosen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah E Sellmeyer, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Many drugs can affect bone metabolism. As examples, heparin, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, glucocorticoids, <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>, cancer drugs, and thyroid hormone can cause bone loss, whereas thiazide diuretics can minimize bone loss [<a href="#rid1">1,2</a>]. This topic will review the skeletal effects of some of these drugs. The effects of glucocorticoids, aromatase inhibitors, and thyroid hormone are discussed separately. (See  <a class="medical medical_review" href="/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis"</a> and  <a class="medical medical_review" href="/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a> and  <a class="medical medical_review" href="/d/html/7882.html" rel="external">"Bone disease with hyperthyroidism and thyroid hormone therapy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DRUGS THAT MAY HAVE ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H3"><span class="h2">Anticoagulants</span></p><p class="headingAnchor" id="H4"><span class="h3">Heparin</span><span class="headingEndMark"> — </span>Heparin causes bone loss by decreasing bone formation. The few studies of the mechanisms underlying this bone loss have revealed decreased bone formation [<a href="#rid3">3</a>], increasing bone resorption, or both [<a href="#rid4">4</a>].</p><p>Since heparin is usually given for brief periods of time, its adverse effect on the skeleton should be trivial. However, it may be given for a prolonged period during pregnancy since <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is relatively contraindicated in the first trimester due to its teratogenic effects [<a href="#rid5">5</a>]. As a result, most of the information concerning the adverse effects of heparin on bone comes from studies of pregnant women requiring anticoagulation.</p><p>Chronic heparin therapy reduces bone mineral density (BMD) [<a href="#rid6">6-8</a>]. In one study, for example, in 14 heparin-treated pregnant women and 14 untreated pregnant women, mean hip density fell by approximately 5 percent in the women receiving heparin; in contrast, BMD did not change in the control group [<a href="#rid6">6</a>]. Hip density decreased by more than 10 percent in 5 of the 14 women taking heparin (36 percent) versus no women in the control group. Similar results were reported in another controlled study, which examined the effect of heparin on forearm density [<a href="#rid7">7</a>].</p><p>There are many case reports and series of pregnant women with osteoporotic fractures during and after prolonged heparin therapy [<a href="#rid9">9</a>]. One of the largest studies followed 184 pregnant women who were given heparin; four (2.2 percent) had osteoporotic vertebral fractures [<a href="#rid9">9</a>]. Although the incidence of fractures was low, they occurred in young women in whom osteoporotic fractures are extremely rare. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p>Bone density increases postpartum after heparin is discontinued [<a href="#rid6">6-8</a>]. It is unclear, however, if recovery is complete.</p><p class="headingAnchor" id="H5"><span class="h3">Low molecular weight heparin</span><span class="headingEndMark"> — </span>Low molecular weight heparins may have less of an adverse effect on bone than <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> [<a href="#rid10">10,11</a>]. However, these trials were small, and a larger, prospective observational study found no difference between the two heparin preparations [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Warfarin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> decreases the tendency of blood to clot by inhibiting the vitamin K-dependent gamma-carboxylation of clotting factors II, VII, IX, and X [<a href="#rid5">5</a>]. Noncarboxylated clotting factors do not bind to calcium and, therefore, cannot participate in the coagulation cascade. Similarly, warfarin inhibits the gamma-carboxylation of osteocalcin, a major protein of bone that is involved in bone formation; noncarboxylated osteocalcin cannot to bind calcium effectively [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.)</p><p>As a result of the latter observation, it has been suspected that <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may adversely affect skeletal health. This hypothesis is indirectly supported by the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Mean serum vitamin K concentrations in patients who have fractures are lower than in individuals without fracture history [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The percentage of noncarboxylated osteocalcin in the serum of older women (who have a greater fracture risk) is higher than in young women [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of hip fracture in women with high serum concentrations of noncarboxylated osteocalcin is higher (relative risk [RR] 5.9) than in women with low concentrations [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of postmenopausal women with vitamin K reduces urinary excretion of hydroxyproline, a marker of bone resorption [<a href="#rid18">18</a>].</p><p></p><p>The clinical importance of these observations is uncertain. Some cross-sectional studies have found that mean bone density in warfarin-treated patients was lower than in control patients [<a href="#rid19">19-21</a>], and a retrospective cohort study found that long-term exposure to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> was associated with an increased risk of vertebral and rib fractures [<a href="#rid22">22</a>]. Low bone density was also reported in a small case-control study of children on long-term warfarin versus control children [<a href="#rid23">23</a>]. In a retrospective cohort study of hospitalized patients with atrial fibrillation, men, but not women, who had taken warfarin for more than one year were at increased risk for osteoporotic fracture (odds ratio [OR] 1.63, 95% CI 1.26-2.10) [<a href="#rid24">24</a>].</p><p>However, in other studies, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> had no adverse effect on bone density [<a href="#rid25">25,26</a>] or fracture rates [<a href="#rid27">27-29</a>]. In a prospective observational study of women aged 65 years and older, for example, those taking warfarin (n = 149) and those not taking it (n = 6052) had similar rates of bone loss at the hip (1.1 and 0.8 percent, respectively) over two years and similar fracture rates over 3.5 years of follow-up [<a href="#rid27">27</a>].</p><p>Other oral anticoagulants do not work on the vitamin K pathway and would not be expected to have an adverse effect on BMD. Some [<a href="#rid30">30-33</a>], but not all [<a href="#rid34">34</a>], observational studies suggest that direct oral anticoagulants (DOACs) are associated with lower risk of fractures than <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. The reason for this difference in fracture risk, if real, is unknown. Nor is it clear whether it represents an increase in risk with warfarin or a decrease in risk with DOACs. If there is a causal association between warfarin and fracture risk, the effect is small. When anticoagulation is indicated, generally fracture risk is not a factor in the selection of an agent.</p><p class="headingAnchor" id="H7"><span class="h2">Cyclosporine</span><span class="headingEndMark"> — </span>Abundant animal data suggest that <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> adversely affects bone. Administration of cyclosporine to rats, for example, causes an increase in both bone resorption and bone loss, or "high-turnover" osteoporosis [<a href="#rid35">35-37</a>].</p><p>There is some evidence that <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> may increase bone turnover in humans as it does in rats [<a href="#rid38">38,39</a>]. However, the effect of cyclosporine on bone metabolism in humans is less clear, being confounded by the presence of other illnesses or drugs that affect bone, particularly glucocorticoids (see  <a class="medical medical_review" href="/d/html/2043.html" rel="external">"Prevention and treatment of osteoporosis after solid organ or stem cell transplantation"</a>). As an example, one study evaluated BMD and bone histology in 20 living, related donor kidney transplant recipients treated with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, cyclosporine, and low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid38">38</a>]. These patients lost 6.8 percent of their initial bone mass during the first six months after transplantation due to a low-turnover bone disorder resembling that induced by glucocorticoids. By 18 months, bone density had decreased 9 percent from baseline, and 60 percent of the patients had BMD values below the fracture threshold. (See  <a class="medical medical_review" href="/d/html/7299.html" rel="external">"Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation"</a>.)</p><p>In contrast, another randomized study compared <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> with placebo in patients with primary biliary cholangitis [<a href="#rid39">39</a>]. Patients receiving cyclosporine had evidence of increased bone turnover; however, cyclosporine decreased the bone loss that normally occurs in this disorder. (See  <a class="medical medical_review" href="/d/html/3606.html" rel="external">"Evaluation and treatment of low bone mass in primary biliary cholangitis (primary biliary cirrhosis)"</a>.)</p><p>Thus, bone loss is common in many of the illnesses treated with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, but the role of cyclosporine alone has not been determined. We currently do not recommend any specific treatment directed toward bone in patients taking cyclosporine.</p><p class="headingAnchor" id="H8"><span class="h2">Medroxyprogesterone acetate</span><span class="headingEndMark"> — </span>The low doses (5 to 10 mg/day) of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> that are typically used in combination with estrogen as part of a regimen of postmenopausal hormone therapy have no effect on the ability of estrogen to prevent bone loss. This issue was best addressed in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial in which 875 women were randomly assigned to placebo or one of four treatment arms consisting of conjugated estrogens (0.625 mg/day) alone or with three different progestin regimens [<a href="#rid40">40</a>]. At three years, BMD increased similarly in all treatment groups and fell in the placebo group. (See  <a class="medical medical_review" href="/d/html/7428.html" rel="external">"Menopausal hormone therapy in the prevention and treatment of osteoporosis"</a>.)</p><p>In contrast, the higher doses of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> that have been used to treat gynecologic disorders have been associated with increased bone loss, presumably due to the induction of estrogen deficiency. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Vitamin A and synthetic retinoids</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">Vitamin A</a> is required for normal growth, vision, reproduction, cell proliferation, and cell differentiation. However, excess intake appears to increase the risk of hip fracture in women. The mechanism by which this may occur has been studied in animals, in which vitamin A inhibited osteoblast activity, stimulated osteoclast formation [<a href="#rid41">41</a>], and counteracted the ability of vitamin D to maintain normal serum calcium concentrations [<a href="#rid42">42</a>], thereby leading to accelerated bone resorption and fractures. The data in humans have been conflicting, but at least four studies have found an association between excess vitamin A intake and osteoporotic fracture:</p><p class="bulletIndent1"><span class="glyph">●</span>The first was a nested case-control study in Sweden, where both <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> intake and the incidence of hip fracture are high [<a href="#rid43">43</a>]. In this report, there was a 10 percent reduction in femoral BMD and a doubling in the risk of hip fracture (OR 2.1, 95% CI 1.1-4.0) among women who consumed more than 1500 mcg retinol per day compared with women who consumed less than 500 mcg per day. The risk was graded; for every 1 mg increase in daily retinol intake, the risk for hip fracture increased by 68 percent (95% CI 18-140 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The same group in Sweden reported similar findings in men. In a prospective cohort study of 2322 men followed for up to 30 years, the risk of any fracture or hip fracture was increased in those whose serum retinol concentrations were in the highest quintile as compared with the middle quintile (RR 1.6, 95% CI 1.1-2.4 and 2.5, 95% CI 1.1-5.3, respectively) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective analysis from the Nurses' Health Study, 603 women had incident hip fractures resulting from low or moderate trauma during 18 years of study [<a href="#rid45">45</a>]. After controlling for confounding factors, women in the highest quintile of <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> intake (≥3000 mcg/day of retinol equivalents) had an increased risk of hip fracture (RR 1.48, 95% CI 1.05-2.07) compared with women in the lowest quintile of intake (&lt;1250 mcg/day of retinol equivalents). The association between high vitamin A intake and hip fracture was not seen with <a class="drug drug_general" data-topicid="9127" href="/d/drug information/9127.html" rel="external">beta-carotene</a> intake and was attenuated in women taking postmenopausal hormone therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Rancho Bernardo Study, a community-based cohort study of older individuals, both low and high <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> intakes were associated with a lower BMD. Bone density was optimal when vitamin A intake was 2000 to 2800 international units per day (0.6 to 0.9 mg/day) [<a href="#rid46">46</a>].</p><p></p><p>Not all studies find a relationship between <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> intake and bone loss. In an analysis from the National Health and Nutrition Examination Survey (NHANES) study, high serum retinyl ester concentrations (a marker of vitamin A intake) were not associated with a decrease in BMD [<a href="#rid47">47</a>]. Similarly, a case-control study of patients with incident osteoporotic fractures, serum indices of vitamin A exposure were not predictive of hip fracture or of lower BMD [<a href="#rid48">48</a>].</p><p>Based upon the available bone density and fracture data, individuals in Western countries should be cautioned against excessive <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> intake. Common food sources of vitamin A include liver, milk, egg yolk, butter, and some fruits and vegetables; those with diets high in these foods should avoid supplements containing vitamin A. (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Requirements'</a> and  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention"</a>.)</p><p>On the other hand, <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> deficiency is still fairly common in African and Asian countries, and inadequate vitamin A intake may also increase fracture risk [<a href="#rid49">49</a>]. For populations in which vitamin A deficiency is endemic, supplementation is recommended. (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Deficiency'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Loop diuretics</span><span class="headingEndMark"> — </span>Loop diuretics increase calcium loss by impairing reabsorption in the loop of Henle (see  <a class="medical medical_review" href="/d/html/2340.html" rel="external">"Diuretics and calcium balance", section on 'Loop of Henle and loop diuretics'</a>). The ensuing negative calcium balance has been associated with a decrease in BMD and an increase in risk of hip fracture in some [<a href="#rid50">50-52</a>], but not all [<a href="#rid53">53</a>], studies. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a clinical trial of 87 healthy, postmenopausal women randomly assigned to receive <a class="drug drug_general" data-topicid="9168" href="/d/drug information/9168.html" rel="external">bumetanide</a>, a loop diuretic, or placebo for one year, urinary calcium and serum parathyroid hormone (PTH) increased (17 and 9 percent, respectively), and BMD decreased at the hip (-2 percent) and whole body (-1.4 percent) in the treatment group compared with placebo [<a href="#rid50">50</a>]. This detrimental effect on bone occurred despite supplementation with calcium and vitamin D.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort study of 3269 men, the use of loop diuretics was also associated with a greater decline in total hip BMD compared with nonuse (annual rate of decline -0.78 versus -0.33 percent, respectively) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study, the adjusted RR for hip fracture was 3.9 (95% CI 1.5-10.4) in patients taking <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> compared with patients not taking furosemide [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, in the Women's Health Initiative (WHI) observational study, there were no significant associations between use of loop diuretics and changes in BMD, falls, and fractures (hazard ratio [HR] for hip fractures in users versus never users 1.21, 95% CI 0.91-1.60) in models adjusted for confounding variables [<a href="#rid53">53</a>]. Women who used loop diuretics were in poorer health and had more risk factors for fracture than never users. However, one-third of loop diuretic users were taking hormone therapy, and mean calcium intake was 1000 mg daily, interventions that may have decreased fracture incidence.</p><p></p><p>The effect of loop diuretics is in contrast to that of thiazide diuretics, which reduce calcium excretion and may increase BMD. (See <a class="local">'Thiazide diuretics'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h2">Chemotherapeutic drugs</span><span class="headingEndMark"> — </span>Most cases of osteoporosis in patients treated for cancer are due to either the hypogonadism that results from chemotherapy and radiation therapy (from the blockade of estrogen synthesis with aromatase inhibitors), or to glucocorticoid therapy [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a> and  <a class="medical medical_review" href="/d/html/745.html" rel="external">"Overview of side effects of chemotherapy for early-stage breast cancer", section on 'Risk factors'</a>.)</p><p>However, direct negative skeletal effects have been described for certain chemotherapeutic drugs:</p><p class="headingAnchor" id="H12"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span>High-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> regimens (such as those used for osteosarcoma or acute lymphoblastic leukemia) are associated with an increase in bone resorption and an inhibition of bone formation, resulting in both osteoporosis and fractures [<a href="#rid54">54,55</a>]. However, this has only rarely been observed with methotrexate in the dose range used for rheumatic disease [<a href="#rid56">56,57</a>]. (See  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Others'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Ifosfamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">Ifosfamide</a> can damage the proximal tubules, causing metabolic acidosis, renal phosphate loss, hypercalciuria, and, in severe cases, hypophosphatemic osteomalacia. (See  <a class="medical medical_review" href="/d/html/2383.html" rel="external">"Ifosfamide nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Imatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> mesylate, a drug used in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and other malignancies, may be associated with changes in bone turnover [<a href="#rid58">58,59</a>]. In one preliminary report, patients receiving imatinib had increases in markers of bone formation (serum osteocalcin and N-terminal propeptide of type I procollagen [PINP]) but no change in a marker of bone resorption (beta isomer of C-terminal telopeptide of type I collagen) within three months of initiating therapy [<a href="#rid59">59</a>]. In some instances, changes in bone turnover were associated with low-normal serum calcium, secondary hyperparathyroidism, renal phosphate wasting, and hypophosphatemia [<a href="#rid58">58,59</a>]. The mechanism and clinical consequences of these findings are unclear. (See  <a class="medical medical_review" href="/d/html/830.html" rel="external">"Hypophosphatemia: Causes of hypophosphatemia"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Antiseizure medications</span><span class="headingEndMark"> — </span>Enzyme-inducing antiseizure medications (ASMs) such as <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a> increase the activity of P450 enzymes. Induction of the cytochrome P450 system by ASMs leads to increased catabolism of vitamin D to inactive metabolites and a subsequent rise in PTH, which increases the mobilization of bone calcium stores and subsequent bone turnover. In ambulatory patients, long-term antiseizure therapy has been associated with low bone density and an increase in fractures. The increase in fracture rate is due to both seizure-related injuries and the adverse effects of ASMs on bone strength. This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/2063.html" rel="external">"Antiseizure medications and bone disease"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Proton pump inhibitors</span><span class="headingEndMark"> — </span>Insoluble calcium, such as <a class="drug drug_general" data-topicid="9185" href="/d/drug information/9185.html" rel="external">calcium carbonate</a>, requires an acid environment for optimal absorption. As a result, drugs that reduce stomach acid secretion (proton pump inhibitors [PPIs] and H2 blockers) may reduce calcium absorption. Because calcium absorption decreases with aging, a further reduction in calcium absorption with the addition of such drugs may have an adverse impact on skeletal health, particularly in older individuals.</p><p>Some [<a href="#rid60">60</a>], but not all [<a href="#rid61">61,62</a>], studies with PPIs show that fractional absorption of calcium is reduced in postmenopausal women. A possible explanation for the different results among studies is a difference in study conditions, including selection of isotope-labeled calcium (<a class="drug drug_general" data-topicid="9185" href="/d/drug information/9185.html" rel="external">calcium carbonate</a> capsules versus <a class="drug drug_general" data-topicid="9186" href="/d/drug information/9186.html" rel="external">calcium chloride</a> solution), method of measurement (fasting serum isotope-labeled calcium levels versus dual isotope measurements with a meal), duration (eg, 7 versus 30 days), type of PPI treatment (<a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> versus a different PPI), and patient characteristics (mean age 76 versus 58 years). Dietary calcium (milk and cheese) absorption was not reduced in healthy individuals treated with omeprazole [<a href="#rid63">63,64</a>], suggesting that a meal induces a sufficient amount of acid secretion for calcium absorption despite PPI therapy.</p><p>The more important clinical question is whether PPIs affect fracture risk. In meta-analyses of case-control and cohort studies, the risk of hip, spine, and any-site fractures was modestly but significantly increased in patients taking PPIs (RRs 1.30, 1.56, and 1.16, respectively) [<a href="#rid65">65-68</a>]. In some studies [<a href="#rid67">67,69</a>], but not another [<a href="#rid70">70</a>], the risk was highest in long-term users of high-dose PPI therapy. In one analysis, the risk was confined to patients with at least one other risk factor for hip fracture [<a href="#rid71">71</a>], and in another, to current or former smokers [<a href="#rid67">67</a>].</p><p>The largest prospective cohort study (the WHI Study) did not find an association between PPI use and hip fracture (HR 1.00, 95% CI 0.71-1.40) [<a href="#rid72">72</a>]. However, PPI use was associated with an increased risk of clinical vertebral (HR 1.47, 95% CI 1.18-1.82), wrist, and total fractures. There was a smaller number of hip fracture events compared with wrist, clinical spine, or total fractures. The lower number of events, combined with the fact that PPI users were more likely than nonusers to be taking hormone therapy, may have reduced the ability of the study to detect an increased risk of hip fracture in PPI users.</p><p>H2 blockers were associated with an increased risk of hip fracture in some reports (adjusted odds ratio [AOR] 1.23, 95% CI 1.14-1.39) [<a href="#rid69">69,71,73</a>] but decreased [<a href="#rid70">70</a>] or unchanged [<a href="#rid68">68,72</a>] risk in others.</p><p>In a subsequent analysis of a national prescription database, concurrent use of PPIs and <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> compared with alendronate alone was associated with loss of protection against hip fracture (fracture risk reduction with alendronate 39 versus 19 percent in non-PPI versus PPI users) [<a href="#rid74">74</a>]. Concurrent treatment with H2 blockers did not modify the treatment response to alendronate.</p><p>Although the association between PPIs and fracture is plausible, these observational studies do not prove causality. One possible mechanism by which PPIs and H2 blockers adversely affect bone is through impaired absorption of <a class="drug drug_general" data-topicid="9185" href="/d/drug information/9185.html" rel="external">calcium carbonate</a> due to achlorhydria, which increases bone loss and reduces BMD. In a prospective cohort study, chronic PPI use was associated with lower baseline BMD at the femoral neck and total hip, but use over 10 years was not associated with accelerated BMD decline [<a href="#rid75">75</a>]. In addition, other studies have not found a decrease in BMD in PPI users compared with nonusers [<a href="#rid76">76,77</a>], albeit in one of these there was an increased risk of falls and fractures in PPI users [<a href="#rid76">76</a>]. Thus, factors independent of BMD (eg, frailty) may contribute to fracture risk, and PPI use may be a marker of frailty since PPI users are, as a group, sicker than controls [<a href="#rid75">75</a>]. Further studies investigating the relationship between PPIs and fracture are required.</p><p>In the interim, because <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> was shown to reduce the fractional absorption of <a class="drug drug_general" data-topicid="9185" href="/d/drug information/9185.html" rel="external">calcium carbonate</a> in fasting postmenopausal women in some studies [<a href="#rid60">60</a>], we advise that postmenopausal women taking long-term PPI or H2 blocker therapy increase dietary calcium and, when necessary, use calcium supplements that do not require acid for absorption, such as <a class="drug drug_general" data-topicid="8829" href="/d/drug information/8829.html" rel="external">calcium citrate</a>. The treatment of postmenopausal women with or at risk for osteoporotic fracture is reviewed separately. (See  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis", section on 'Supplements'</a> and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Low bone mass'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Antidepressants</span><span class="headingEndMark"> — </span>Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased risk of fragility fracture in observational studies [<a href="#rid78">78-80</a>]. In meta-analyses of case-control and cohort studies, there was an increased risk of fracture (predominantly hip and nonvertebral fracture) in patients who had taken an SSRI (RR 1.72, 95% CI 1.51-1.95) [<a href="#rid81">81,82</a>]. Similarly, in a separate meta-analysis of case-control and cohort studies examining the association between TCAs and risk of fracture, there was an increased risk of fracture in users of TCAs compared with nonusers (adjusted RR 1.36, 95% CI 1.24-1.50) [<a href="#rid83">83</a>]. The rise in fracture risk was very rapid and decreased with time, suggesting that the effect was not due to a reduction in BMD. In both meta-analyses, the increased risk persisted after confining the analysis to studies that adjusted for important risk factors for fracture (age, comorbidities, medications known to increase fracture risk, BMD).</p><p>The results from these studies do not prove causality, and other confounders not controlled for during statistical analysis may explain the observed association. However, one mechanism to explain the possible association between antidepressants and fracture is the adverse effects of the drugs, including sedation and postural hypotension, which may increase risk of falls. Nevertheless, in some large cross-sectional and prospective cohort studies, use of SSRIs, but not TCAs, has been associated with reduced BMD in older men [<a href="#rid84">84</a>] and increased rates of bone loss at the hip in older women [<a href="#rid85">85</a>]. Thus, an alternative possibility is a direct effect of SSRIs on bone metabolism, although studies in this regard are preliminary and not supported by limited randomized controlled trials [<a href="#rid86">86,87</a>].</p><p>Prospective trials are needed to definitively determine the relationship between antidepressants and fracture. In the interim, we recommend that the risks of potential fracture be balanced against the benefits gained from treating depression, especially in older persons who are already at increased risk for osteoporosis and fracture. The decision to prescribe SSRIs versus TCAs should not be driven by fracture data, since there are only observational data that either may increase risk of fracture.</p><p>We also recommend counseling regarding fall prevention, adequate calcium and vitamin D supplementation, and smoking cessation, which are important lifestyle changes that may prevent fracture. BMD testing should be considered in patients receiving SSRIs, especially when other risk factors for fracture are present, such as advanced age or prior history of fragility fracture. (See  <a class="medical medical_review" href="/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a> and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Lifestyle measures to reduce bone loss'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Thiazolidinediones</span><span class="headingEndMark"> — </span>There is evidence suggesting that thiazolidinediones have an adverse impact on skeletal health, including an increased risk of fractures in women (humerus, hand, foot). (See  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Safety'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Antiretroviral therapy</span><span class="headingEndMark"> — </span>There is an increased risk of reduced bone density in human immunodeficiency virus (HIV)-infected individuals. Low BMD among patients with HIV infection is usually multifactorial. This topic is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">DRUGS THAT MAY HAVE BENEFICIAL EFFECTS</span></p><p class="headingAnchor" id="H21"><span class="h2">Thiazide diuretics</span><span class="headingEndMark"> — </span>Thiazide diuretics stimulate distal tubular reabsorption of calcium, leading to a decrease in urinary calcium excretion. This effect is used clinically to reduce the frequency of stone formation in patients with recurrent nephrolithiasis and hypercalciuria. (See  <a class="medical medical_review" href="/d/html/2340.html" rel="external">"Diuretics and calcium balance"</a> and  <a class="medical medical_review" href="/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones"</a>.)</p><p>As a result, thiazide diuretics may have a beneficial effect on bone mineral density (BMD). This is in contrast to loop diuretics, which increase calcium excretion and may reduce BMD. (See <a class="local">'Loop diuretics'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h3">Bone mineral density</span><span class="headingEndMark"> — </span>Long-term thiazide therapy may increase bone density and decrease fracture risk. In cross-sectional studies, patients taking a thiazide had a higher bone density than control patients [<a href="#rid88">88,89</a>]. A report of 9704 White women, for example, found that the forearm and calcaneus density was 4 to 5 percent higher in those taking a thiazide, even after correcting for other confounding variables such as body mass index and calcium intake [<a href="#rid88">88</a>].</p><p>There are also clinical trial data that demonstrate a beneficial effect of thiazide diuretics on BMD:</p><p class="bulletIndent1"><span class="glyph">●</span>In a controlled trial of 184 normal postmenopausal women, <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> (50 mg/day for two years) resulted in a significant increase in forearm but not lumbar spine or hip density [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A three-year trial of 320 healthy individuals aged 60 to 79 years examined the effect of <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> (12.5 or 25 mg/day) versus placebo. In women, the hip and spine density was 1.4 and 1.3 percent higher, respectively, in the 25 mg-group compared with the placebo group [<a href="#rid91">91</a>]; the effect of the 12.5 mg dose was smaller. Hydrochlorothiazide also prevented bone loss in men, although the effect was less than in women (0.7 and 0.4 percent versus placebo in the hip and spine, respectively) [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H23"><span class="h3">Fracture risk</span><span class="headingEndMark"> — </span>Most [<a href="#rid88">88,92-98</a>], but not all [<a href="#rid52">52,99</a>], observational studies have shown a beneficial effect of thiazides on fracture risk. A 2011 meta-analysis of 21 observational studies involving almost 400,000 individuals noted a significant reduction in risk of hip fracture with long-term thiazide therapy (RR 0.76, 95% CI 0.64-0.89) [<a href="#rid96">96</a>].</p><p>Although a randomized clinical trial has not been performed, we conclude that thiazide therapy attenuates bone loss and may reduce fracture risk, but the effect is modest. We do not routinely recommend the administration of thiazides to prevent or treat osteoporosis, but a thiazide diuretic is a reasonable choice if a patient with osteoporosis has hypertension or nephrolithiasis.</p><p class="headingAnchor" id="H24"><span class="h2">Statins</span><span class="headingEndMark"> — </span>It has been thought that <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.google.com%2Furl%3Fsa%3Dt%26rct%3Dj%26q%3D%26esrc%3Ds%26frm%3D1%26source%3Dweb%26cd%3D6%26ved%3D0CFgQFjAF%26url%3Dhttp%253A%252F%252Fwww.ncbi.nlm.nih.gov%252Fpmc%252Farticles%252FPMC545772%252F%26ei%3DWy4wU_LxOaKyyAHBp4DwBg%26usg%3DAFQjCNGuKN05XiTsxAfyR46drxJkabqseQ%26sig2%3DgthFWdy5ekjsSYImXDGMIw%26bvm%3Dbv.62922401%2Cd.aWc&amp;token=nL73FSxE9PjTggCR7tKYQT0VTa8PltC3Mk%2FGd7tr%2BkmxkIeKKMxMLgGGoGKQa%2BGR5MT0svQvhAw239Ffx4sPmIOyOd6Gg88UUqyZ8MEgieqdDjyvlioJnFhiWGVz36Fi9f5puEDPJlYBYxJEG2xIM1SKpGNqs3MLYn72Y%2FvLVOWSh21%2BPU81TWwU7RrKWcw8KNtfhU%2B1B9ViYMIK8FfWGUBVjuPJepGM17xR%2BdxKzRaTiEwxXCDUb4RpEqxiWPMgJ3q9luQH9o6ry8nwQesp78zC6WFV74WLYYyzmUzzGGtsV7nMhwgLVk3biEmWNNYj&amp;TOPIC_ID=2036" target="_blank">3-hydroxy-3-methylglutaryl coenzyme-A</a> (HMG-CoA) reductase inhibitors (statins), which are used for the treatment of hypercholesterolemia, may have beneficial effects on the skeleton, but data are conflicting. In some studies, statin therapy was associated with a decrease in fractures or an increase in bone density [<a href="#rid100">100-105</a>], but in others, there was no decrease in fractures [<a href="#rid106">106-108</a>]. Many of the studies included men (sometimes in a majority), the particular statin varied, and the design of the studies varied. Most were case-control or retrospective studies.</p><p>The Women's Health Initiative (WHI) observational study, the largest observational study to address this issue, reported no reduction in fracture rates in postmenopausal statin users compared with nonusers after four years of follow-up [<a href="#rid109">109</a>]. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p>In a meta-analysis of eight observational studies that reported statin use and documented fracture outcomes in postmenopausal women (including the WHI observational study noted above), statin use was associated with a lower risk of hip fracture (odds ratio [OR] 0.43, 95% CI 0.25-0.75 for users versus nonusers) [<a href="#rid110">110</a>]. However, post hoc analyses of two cardiovascular trials did not support a protective effect [<a href="#rid106">106,108</a>].</p><p>In the one clinical trial to date, 82 postmenopausal women were randomly assigned to <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> (40 mg/day) or placebo for one year. There were no effects of simvastatin on biochemical bone markers or on BMD at the hip or spine, although an increase in bone density was seen in the forearm. Thus, observational data on statin use and beneficial effects on bone health have been conflicting, but in the one randomized clinical trial to address this, simvastatin did not appear to have an overall beneficial effect on bone [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Nitrates</span><span class="headingEndMark"> — </span>Nitric oxide slows bone remodeling and bone loss in animals [<a href="#rid112">112</a>]. In observational studies in humans, nitrate administration, which increases nitric oxide levels, was associated with an increase in BMD [<a href="#rid113">113</a>] and a reduction in fracture risk [<a href="#rid114">114</a>]. However, a randomized trial did not show benefit. In a three-year trial of <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> ointment (22.5 mg/day) versus placebo in 186 postmenopausal women without osteoporosis (BMD T-scores between 0 and -2.5 and no prior vertebral or hip fracture), women in both groups had similar reductions in lumbar spine and total hip BMD after 36 months (-2.06 versus -2.48 percent and -4.38 versus -4.03 percent for lumbar spine and total hip, respectively) [<a href="#rid115">115</a>]. The trial was not powered to assess fracture outcomes. Headaches were a common side effect, occurring in 57 percent of women in the nitroglycerin group.</p><p class="headingAnchor" id="H26"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>In animal models, beta blockers stimulate bone formation and inhibit bone resorption [<a href="#rid116">116</a>]. Data in humans are inconsistent, with some studies showing a lower risk of fracture with current use of beta blockers [<a href="#rid117">117,118</a>] and another showing no effect [<a href="#rid119">119</a>]. A meta-analysis of 16 observational studies showed a significant reduction in fracture risk in patients receiving beta blockers, a finding primarily driven by a reduction in risk of hip fracture [<a href="#rid120">120</a>]. The meta-analysis was limited by significant heterogeneity in the results.</p><p>Given the limitations of the observational data and the absence of clinical trial data, beta blockers have no current role in osteoporosis management.</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-related skeletal effects </strong>– There are several drugs that have been associated with a decrease in bone mineral density (BMD) and an increase in the risk of fracture, whereas other drugs appear to improve BMD and decrease the risk of fracture. (See <a class="local">'Drugs that may have adverse effects'</a> above and <a class="local">'Drugs that may have beneficial effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drugs that may have adverse effects on bone</strong> – In observational studies, commonly used medications, such as proton pump inhibitors (PPIs), antidepressants, anticoagulants, and loop diuretics have been associated with an increased risk of fracture. (See <a class="local">'Drugs that may have adverse effects'</a> above.)</p><p></p><p class="bulletIndent2">When these medications are given for a brief period of time, the adverse skeletal effects are of less concern. Because long-term therapy may have detrimental skeletal effects, older patients should be evaluated for other risk factors for osteoporosis and fracture. BMD testing should be considered in some patients, especially when other risk factors for fracture are present, such as advanced age or prior history of fragility fracture. Older patients should receive counseling regarding fall prevention, adequate calcium and vitamin D supplementation, and smoking cessation, which are important lifestyle changes that may prevent fracture. (See  <a class="medical medical_review" href="/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a> and  <a class="medical medical_review" href="/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drugs that may have beneficial effects on bone</strong> – Long-term thiazide therapy may increase bone density and decrease fracture risk. Data are inconsistent for the effects of statins, nitrates, and beta blockers on BMD and fracture risk. None of these medications are recommended specifically for skeletal protection. (See <a class="local">'Drugs that may have beneficial effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-mediated effects on bone</strong> – The skeletal effects of glucocorticoids are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Davidge Pitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011; 86:338.</a></li><li><a class="nounderline abstract_t">Watts NB. Adverse bone effects of medications used to treat non-skeletal disorders. Osteoporos Int 2017; 28:2741.</a></li><li><a class="nounderline abstract_t">van der Wiel HE, Lips P, Huijgens PC, Netelenbos JC. Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover. Bone Miner 1993; 22:27.</a></li><li><a class="nounderline abstract_t">Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996; 88:1314.</a></li><li><a class="nounderline abstract_t">Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324:1865.</a></li><li><a class="nounderline abstract_t">Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170:862.</a></li><li><a class="nounderline abstract_t">Dahlman TC, Sjöberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170:1315.</a></li><li><a class="nounderline abstract_t">Dahlman T, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol 1990; 97:221.</a></li><li><a class="nounderline abstract_t">Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265.</a></li><li><a class="nounderline abstract_t">Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71:7.</a></li><li><a class="nounderline abstract_t">Pettilä V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87:182.</a></li><li><a class="nounderline abstract_t">Backos M, Rai R, Thomas E, et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14:2876.</a></li><li><a class="nounderline abstract_t">Lian JB, Gundberg CM. Osteocalcin. Biochemical considerations and clinical applications. Clin Orthop Relat Res 1988; :267.</a></li><li><a class="nounderline abstract_t">Hodges SJ, Akesson K, Vergnaud P, et al. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 1993; 8:1241.</a></li><li><a class="nounderline abstract_t">Bitensky L, Hart JP, Catterall A, et al. Circulating vitamin K levels in patients with fractures. J Bone Joint Surg Br 1988; 70:663.</a></li><li><a class="nounderline abstract_t">Plantalech L, Guillaumont M, Vergnaud P, et al. Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. J Bone Miner Res 1991; 6:1211.</a></li><li><a class="nounderline abstract_t">Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993; 91:1769.</a></li><li><a class="nounderline abstract_t">Knapen MH, Hamulyák K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 1989; 111:1001.</a></li><li><a class="nounderline abstract_t">Fiore CE, Tamburino C, Foti R, Grimaldi D. Reduced axial bone mineral content in patients taking an oral anticoagulant. South Med J 1990; 83:538.</a></li><li><a class="nounderline abstract_t">Philip WJ, Martin JC, Richardson JM, et al. Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 1995; 88:635.</a></li><li><a class="nounderline abstract_t">Nalevaiko JZ, Marques JVO, Oliveira MF, et al. Bone density and quality in patients treated with direct-acting oral anticoagulants versus warfarin. Bone 2021; 150:116000.</a></li><li><a class="nounderline abstract_t">Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999; 159:1750.</a></li><li><a class="nounderline abstract_t">Barnes C, Newall F, Ignjatovic V, et al. Reduced bone density in children on long-term warfarin. Pediatr Res 2005; 57:578.</a></li><li><a class="nounderline abstract_t">Gage BF, Birman-Deych E, Radford MJ, et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 166:241.</a></li><li><a class="nounderline abstract_t">Piro LD, Whyte MP, Murphy WA, Birge SJ. Normal cortical bone mass in patients after long term coumadin therapy. J Clin Endocrinol Metab 1982; 54:470.</a></li><li><a class="nounderline abstract_t">Rosen HN, Maitland LA, Suttie JW, et al. Vitamin K and maintenance of skeletal integrity in adults. Am J Med 1993; 94:62.</a></li><li><a class="nounderline abstract_t">Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 128:829.</a></li><li><a class="nounderline abstract_t">Woo C, Chang LL, Ewing SK, et al. Single-point assessment of warfarin use and risk of osteoporosis in elderly men. J Am Geriatr Soc 2008; 56:1171.</a></li><li><a class="nounderline abstract_t">Veronese N, Bano G, Bertozzo G, et al. Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis. J Thromb Haemost 2015; 13:1665.</a></li><li><a class="nounderline abstract_t">Lutsey PL, Norby FL, Ensrud KE, et al. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation. JAMA Intern Med 2020; 180:245.</a></li><li><a class="nounderline abstract_t">Lau WCY, Man KKC, Wong ICK. Vitamin K Antagonist Use and Fracture. J Gen Intern Med 2020; 35:396.</a></li><li><a class="nounderline abstract_t">Binding C, Bjerring Olesen J, Abrahamsen B, et al. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. J Am Coll Cardiol 2019; 74:2150.</a></li><li><a class="nounderline abstract_t">Huang HK, Liu PP, Hsu JY, et al. Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin. J Am Heart Assoc 2020; 9:e013845.</a></li><li><a class="nounderline abstract_t">Fiordellisi W, White K, Schweizer M. A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture. J Gen Intern Med 2019; 34:304.</a></li><li><a class="nounderline abstract_t">Bryer HP, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995; 10:132.</a></li><li><a class="nounderline abstract_t">Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123:2571.</a></li><li><a class="nounderline abstract_t">Mann GN, Jacobs TW, Buchinsky FJ, et al. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 1994; 135:1077.</a></li><li><a class="nounderline abstract_t">Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325:544.</a></li><li><a class="nounderline abstract_t">Guañabens N, Parés A, Navasa M, et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol 1994; 21:24.</a></li><li><a class="nounderline abstract_t">Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276:1389.</a></li><li><a class="nounderline abstract_t">Togari A, Kondo M, Arai M, Matsumoto S. Effects of retinoic acid on bone formation and resorption in cultured mouse calvaria. Gen Pharmacol 1991; 22:287.</a></li><li><a class="nounderline abstract_t">Rohde CM, Manatt M, Clagett-Dame M, DeLuca HF. Vitamin A antagonizes the action of vitamin D in rats. J Nutr 1999; 129:2246.</a></li><li><a class="nounderline abstract_t">Melhus H, Michaëlsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med 1998; 129:770.</a></li><li><a class="nounderline abstract_t">Michaëlsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med 2003; 348:287.</a></li><li><a class="nounderline abstract_t">Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002; 287:47.</a></li><li><a class="nounderline abstract_t">Promislow JH, Goodman-Gruen D, Slymen DJ, Barrett-Connor E. Retinol intake and bone mineral density in the elderly: the Rancho Bernardo Study. J Bone Miner Res 2002; 17:1349.</a></li><li><a class="nounderline abstract_t">Ballew C, Galuska D, Gillespie C. High serum retinyl esters are not associated with reduced bone mineral density in the Third National Health And Nutrition Examination Survey, 1988-1994. J Bone Miner Res 2001; 16:2306.</a></li><li><a class="nounderline abstract_t">Barker ME, McCloskey E, Saha S, et al. Serum retinoids and beta-carotene as predictors of hip and other fractures in elderly women. J Bone Miner Res 2005; 20:913.</a></li><li><a class="nounderline abstract_t">Opotowsky AR, Bilezikian JP, NHANES I follow-up study. Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up study. Am J Med 2004; 117:169.</a></li><li><a class="nounderline abstract_t">Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 2006; 21:163.</a></li><li><a class="nounderline abstract_t">Lim LS, Fink HA, Kuskowski MA, et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 2008; 168:735.</a></li><li><a class="nounderline abstract_t">Heidrich FE, Stergachis A, Gross KM. Diuretic drug use and the risk for hip fracture. Ann Intern Med 1991; 115:1.</a></li><li><a class="nounderline abstract_t">Carbone LD, Johnson KC, Bush AJ, et al. Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch Intern Med 2009; 169:132.</a></li><li><a class="nounderline abstract_t">Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18:1570.</a></li><li><a class="nounderline abstract_t">Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 11:13.</a></li><li><a class="nounderline abstract_t">Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993; 52:582.</a></li><li><a class="nounderline abstract_t">Rolvien T, Creutzfeldt AM, Lohse AW, Amling M. Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy. Lupus 2019; 28:790.</a></li><li><a class="nounderline abstract_t">Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.</a></li><li><a class="nounderline abstract_t">Grey A, O'Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006; 355:2494.</a></li><li><a class="nounderline abstract_t">O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118:778.</a></li><li><a class="nounderline abstract_t">Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010; 25:2786.</a></li><li><a class="nounderline abstract_t">Hansen KE, Nieves JW, Nudurupati S, et al. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women. Gastroenterology 2019; 156:926.</a></li><li><a class="nounderline abstract_t">Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995; 14:364.</a></li><li><a class="nounderline abstract_t">Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010; 25:2205.</a></li><li><a class="nounderline abstract_t">Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124:519.</a></li><li><a class="nounderline abstract_t">Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106:1209.</a></li><li><a class="nounderline abstract_t">Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344:e372.</a></li><li><a class="nounderline abstract_t">Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011; 48:768.</a></li><li><a class="nounderline abstract_t">Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79:76.</a></li><li><a class="nounderline abstract_t">Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139:93.</a></li><li><a class="nounderline abstract_t">Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170:765.</a></li><li><a class="nounderline abstract_t">de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20:1989.</a></li><li><a class="nounderline abstract_t">Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 171:998.</a></li><li><a class="nounderline abstract_t">Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107:1361.</a></li><li><a class="nounderline abstract_t">Lewis JR, Barre D, Zhu K, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 2014; 29:2489.</a></li><li><a class="nounderline abstract_t">Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res 2015; 30:232.</a></li><li><a class="nounderline abstract_t">Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351:1303.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163:949.</a></li><li><a class="nounderline abstract_t">Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167:188.</a></li><li><a class="nounderline abstract_t">Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012; 23:365.</a></li><li><a class="nounderline abstract_t">Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 2012; 27:1186.</a></li><li><a class="nounderline abstract_t">Wu Q, Qu W, Crowell MD, et al. Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies. J Bone Miner Res 2013; 28:753.</a></li><li><a class="nounderline abstract_t">Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167:1246.</a></li><li><a class="nounderline abstract_t">Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:1240.</a></li><li><a class="nounderline abstract_t">Battaglino R, Fu J, Späte U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004; 19:1420.</a></li><li><a class="nounderline abstract_t">Diem SJ, Joffe H, Larson JC, et al. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J Clin Endocrinol Metab 2014; 99:E1732.</a></li><li><a class="nounderline abstract_t">Cauley JA, Cummings SR, Seeley DG, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118:666.</a></li><li><a class="nounderline abstract_t">Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1996; 124:187.</a></li><li><a class="nounderline abstract_t">Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000; 109:362.</a></li><li><a class="nounderline abstract_t">LaCroix AZ, Ott SM, Ichikawa L, et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 133:516.</a></li><li><a class="nounderline abstract_t">Felson DT, Sloutskis D, Anderson JJ, et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991; 265:370.</a></li><li><a class="nounderline abstract_t">Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139:476.</a></li><li><a class="nounderline abstract_t">LaCroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990; 322:286.</a></li><li><a class="nounderline abstract_t">Ray WA, Griffin MR, Downey W, Melton LJ 3rd. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989; 1:687.</a></li><li><a class="nounderline abstract_t">Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev 2011; :CD005185.</a></li><li><a class="nounderline abstract_t">Puttnam R, Davis BR, Pressel SL, et al. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med 2017; 177:67.</a></li><li><a class="nounderline abstract_t">Xiao X, Xu Y, Wu Q. Thiazide diuretic usage and risk of fracture: a meta-analysis of cohort studies. Osteoporos Int 2018; 29:1515.</a></li><li><a class="nounderline abstract_t">Paik JM, Rosen HN, Gordon CM, Curhan GC. Diuretic Use and Risk of Vertebral Fracture in Women. Am J Med 2016; 129:1299.</a></li><li><a class="nounderline abstract_t">Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283:3211.</a></li><li><a class="nounderline abstract_t">Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85:1137.</a></li><li><a class="nounderline abstract_t">Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355:2185.</a></li><li><a class="nounderline abstract_t">Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162:537.</a></li><li><a class="nounderline abstract_t">Scranton RE, Young M, Lawler E, et al. Statin use and fracture risk: study of a US veterans population. Arch Intern Med 2005; 165:2007.</a></li><li><a class="nounderline abstract_t">Seo DH, Jeong Y, Cho Y, et al. Age- and dose-dependent effect of statin use on the risk of osteoporotic fracture in older adults. Osteoporos Int 2023; 34:1927.</a></li><li><a class="nounderline abstract_t">El-Sohemy A. Statin drugs and the risk of fracture. JAMA 2000; 284:1921.</a></li><li><a class="nounderline abstract_t">van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285:1850.</a></li><li><a class="nounderline abstract_t">Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001; 357:509.</a></li><li><a class="nounderline abstract_t">LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003; 139:97.</a></li><li><a class="nounderline abstract_t">Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164:146.</a></li><li><a class="nounderline abstract_t">Rejnmark L, Buus NH, Vestergaard P, et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004; 19:737.</a></li><li><a class="nounderline abstract_t">Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996; 18:301.</a></li><li><a class="nounderline abstract_t">Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 1998; 13:1755.</a></li><li><a class="nounderline abstract_t">Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 2006; 21:1811.</a></li><li><a class="nounderline abstract_t">Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab 2009; 94:3356.</a></li><li><a class="nounderline abstract_t">Cherruau M, Facchinetti P, Baroukh B, Saffar JL. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 1999; 25:545.</a></li><li><a class="nounderline abstract_t">Pasco JA, Henry MJ, Sanders KM, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004; 19:19.</a></li><li><a class="nounderline abstract_t">Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004; 292:1326.</a></li><li><a class="nounderline abstract_t">Reid IR, Gamble GD, Grey AB, et al. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20:613.</a></li><li><a class="nounderline abstract_t">Toulis KA, Hemming K, Stergianos S, et al. β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int 2014; 25:121.</a></li></ol></div><div id="topicVersionRevision">Topic 2036 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21389249" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Update on medications with adverse skeletal effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28752332" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adverse bone effects of medications used to treat non-skeletal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8219935" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8695849" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1801769" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Oral anticoagulant drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141217" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178860" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bone mineral density during long-term prophylaxis with heparin in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110467" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8475973" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8165649" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11858475" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10548640" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275514" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Osteocalcin. Biochemical considerations and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256661" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3403621" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Circulating vitamin K levels in patients with fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1666807" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8473517" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2556952" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2343333" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reduced axial bone mineral content in patients taking an oral anticoagulant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7583077" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Decreased axial and peripheral bone density in patients taking long-term warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33971316" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bone density and quality in patients treated with direct-acting oral anticoagulants versus warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10448778" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term use of oral anticoagulants and the risk of fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695604" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reduced bone density in children on long-term warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16432096" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7054229" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Normal cortical bone mass in patients after long term coumadin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420301" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Vitamin K and maintenance of skeletal integrity in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599195" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547361" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Single-point assessment of warfarin use and risk of osteoporosis in elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26179400" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31764956" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31342326" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Vitamin K Antagonist Use and Fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31648707" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31918601" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30511289" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7747620" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3262506" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8070349" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1857390" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rapid loss of vertebral mineral density after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7963418" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892713" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2055423" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of retinoic acid on bone formation and resorption in cultured mouse calvaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573558" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Vitamin A antagonizes the action of vitamin D in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841582" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12540641" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serum retinol levels and the risk of fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11754708" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vitamin A intake and hip fractures among postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12162487" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Retinol intake and bone mineral density in the elderly: the Rancho Bernardo Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11760846" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : High serum retinyl esters are not associated with reduced bone mineral density in the Third National Health And Nutrition Examination Survey, 1988-1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883630" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum retinoids and beta-carotene as predictors of hip and other fractures in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15276595" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355285" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413556" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2048857" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diuretic drug use and the risk for hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171809" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735906" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Osteoporosis due to cancer treatment: pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6424236" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Methotrexate osteopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215620" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Methotrexate osteopathy in rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30947618" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687713" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Altered bone and mineral metabolism in patients receiving imatinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17151376" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15989913" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578215" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Do proton pump inhibitors decrease calcium absorption?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30445008" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568113" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20499372" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605729" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21483462" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22294756" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185417" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Meta-analysis: risk of fractures with acid-suppressing medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190895" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term proton pump inhibitor therapy and risk of hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16927047" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20353792" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458083" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333676" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321287" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Proton pump inhibitor use and the antifracture efficacy of alendronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777336" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24825180" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25156141" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643791" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12719205" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Central nervous system active medications and risk for fractures in older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242321" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effect of selective serotonin reuptake inhibitors on the risk of fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21904950" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258738" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23165455" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592097" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592096" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312242" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Serotonin regulates osteoclast differentiation through its transporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25014001" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effects of escitalopram on markers of bone turnover: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8489642" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8533993" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Axial bone mass in older women. Study of Osteoporotic Fractures Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11020392" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11015164" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984536" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679324" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Thiazide diuretics and the risk for hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2296269" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Thiazide diuretic agents and the incidence of hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564506" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term use of thiazide diuretics and risk of hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975748" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Thiazide diuretics and the risk of hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893045" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29574519" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Thiazide diuretic usage and risk of fracture: a meta-analysis of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542612" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Diuretic Use and Risk of Vertebral Fracture in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10866868" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720052" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10881890" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11871921" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186471" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Statin use and fracture risk: study of a US veterans population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37552294" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Age- and dose-dependent effect of statin use on the risk of osteoporotic fracture in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035877" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Statin drugs and the risk of fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11308398" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Use of statins and risk of fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229669" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859159" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744837" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068496" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8726385" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Nitric oxide donor alleviates ovariectomy-induced bone loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797485" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054422" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Decreased fracture risk in users of organic nitrates: a nationwide case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549739" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10574574" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14753732" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367554" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Use of beta-blockers and risk of fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15765180" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114396" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
